预约演示
更新于：2025-10-14
Ropivacaine Hydrochloride
盐酸罗哌卡因
更新于：2025-10-14
概要
基本信息
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C17H29ClN2O2 |
InChIKeyVSHFRHVKMYGBJL-CKUXDGONSA-N |
CAS号132112-35-7 |
关联
2,642
项与 盐酸罗哌卡因 相关的临床试验ChiCTR2500108728
Study on the minimum effective volume and concentration of ropivacaine for thoracoscopic guided-thoracic paravertebral nerve block
ChiCTR2500110198
Effects of Micro-Dose Combined Spinal-Epidural Block on the Onset of Labor Analgesia and Maternal and Neonatal Safety: A Randomized, Double-Blind, Controlled Trial
NCT07209345
Pre-emptive Scalp Infiltration With Low-dose Flurbiprofen and Ropivacaine for Postoperative Analgesia After Craniotomy
100 项与 盐酸罗哌卡因 相关的临床结果
登录后查看更多信息
100 项与 盐酸罗哌卡因 相关的转化医学
登录后查看更多信息
100 项与 盐酸罗哌卡因 相关的专利（医药）
登录后查看更多信息
2,540
项与 盐酸罗哌卡因 相关的文献（医药）2025-12-31ANNALS OF MEDICINE
Liposomal bupivacaine vs. Ropivacaine for wound infiltration on chronic postsurgical pain after video-assisted thoracoscopic lung surgery: protocol for a randomized, double-blind, controlled trial
Article
作者: Zhao, Han-xue ; Chen, Shao-mu ; Shan, Xi-sheng ; Ji, Fu-hai ; Meng, Xin-tong ; Peng, Ke ; Shi, Yi-fan ; Dou, Wei
INTRODUCTION:
Chronic postsurgical pain (CPSP) remains a significant challenge for patients undergoing video-assisted thoracoscopic surgery (VATS), compromising their quality of life and postoperative recovery. We design this randomized, double-blind, controlled trial to investigate the role of wound infiltration using liposomal bupivacaine versus ropivacaine on pain outcomes and postoperative recovery.
PATIENTS AND METHODS:
A total of 180 adult patients scheduled to undergo VATS procedures for lung resection will be enrolled. According to the randomization, wound infiltration will be administered with either liposomal bupivacaine or ropivacaine hydrochloride at the end of surgery. Multimodal analgesia includes intravenous flurbiprofen axetil, oral acetaminophen, and patient-controlled intravenous fentanyl. Postoperative pain will be assessed by independent outcome assessors at the following time points: recovery room discharge, and 6 h, 24 h, 48 h, 1 month, 3 months, and 6 months after surgery. The primary outcome is the incidence of CPSP at 3 months. Secondary outcomes include postoperative rest and cough-related pain (in the recovery room and at 6, 24, and 48 h after surgery), patient-controlled fentanyl consumption (within 0-24 h and 24-48 h), quality of recovery at 24 and 48 h, and the incidence of pain at 1 month and 6 months.
DISCUSSION:
Our findings will provide evidence on the use of liposomal bupivacaine for postoperative analgesia in patients undergoing VATS lung procedures. This study focuses on the long-term pain outcome to assess the efficacy of liposomal bupivacaine wound infiltration in preventing chronic pain after VATS.
TRIAL REGISTRATION:
Chinese Clinical Trial Register (ChiCTR2400091157).
2025-10-03The International journal of neuroscience
The effects of combined acupuncture anesthesia and serratus anterior plane block with ropivacaine on postoperative analgesia in patients undergoing chest surgery
Article
作者: Wu, Zhen ; Wang, Jieqiong ; Wang, Chunfeng ; Shi, Lingyan ; Yu, Xiangyuan ; Cai, Hongqin
OBJECTIVE:
To investigate the effects of combined acupuncture anesthesia and ropivacaine on postoperative analgesia and neuro-related factors in patients undergoing chest surgery.
METHODS:
The analgesic drug dosage, postoperative PCIA pressing times, VAS scores at rest and during activity at 6 h (T1), 12 h (T2), 18 h (T3), and 24 h (T4) postoperatively.
RESULTS:
The analgesic drug dosage and postoperative PCIA pressing times were lower in the observation group than in the control group (p < 0.05). The VAS scores at T1-T4 postoperatively were lower in the observation group than in the control group (p < 0.05). The SAS scores at T1-T4 postoperatively were lower in the observation group than in the control group (p < 0.05). The levels of IL-6 and IL-10 on postoperative day 1 were higher than those on preoperative day 1 in both groups, with a smaller change in the observation group (p < 0.05). The levels of S100β protein on postoperative day 1 were higher than those on preoperative day 1 in both groups, while the BDNF levels were lower, with a smaller change in the observation group (p < 0.05). There was no significant difference in the incidence of adverse reactions between the control group (11.36%) and the observation group (15.56%) (p > 0.05).
CONCLUSION:
Combined acupuncture anesthesia and ropivacaine can effectively improve postoperative analgesia and agitation in patients undergoing chest surgery, reduce the dosage of analgesic drugs, regulate the levels of inflammatory factors and neurotrophic factors in patients, and do not increase the risk of adverse reactions related to patients.
2025-10-01Journal of PeriAnesthesia Nursing
Combination of Ropivacaine Hydrochloride and Esketamine for Thoracic Paravertebral Block on Pain and Postoperative Recovery of Patients Undergoing Radical Resection Surgery for Lung Cancer
Article
作者: Yang, Qun ; Cheng, Feng ; Luo, Qian ; Rao, Li-Hao ; Yang, Ze-Xue ; Zheng, Li-Dong ; Cheng, Lei
PURPOSE:
This study aims to investigate the efficacy of a combination of ropivacaine hydrochloride and esketamine in paravertebral block (PVB), in providing analgesia and promoting the postoperative recovery of patients undergoing elective thoracoscopic radical lung cancer surgery.
DESIGN:
A randomized controlled trial was conducted involving 70 patients scheduled for elective thoracoscopic radical lung cancer surgery.
METHODS:
Participants were randomly assigned to either the esketamine group (K group) or the control group (C group). Patients in the K group were administered a combination of 0.1 mg/kg of esketamine and 0.5% ropivacaine for PVB, while patients in the C group received only 0.5% ropivacaine. The time interval between the patient's discharge from the postanesthesia care unit and the first press of the analgesic pump and the number of presses. Various parameters that were monitored included the patients' mean arterial pressure, heart rate, and oxygen saturation at different time points; levels of interleukin-6, tumor necrosis factor-α, and C-reactive protein in venous blood preoperatively and 6 hours postoperatively; pain assessed using the numeric rating scale scores.
FINDINGS:
Compared with group C, patients in group K had significantly longer intervals before their first postoperative analgesic pump press and significantly fewer effective analgesic pump presses in the 48-hour postoperative period. Resting numeric rating scale scores were significantly lower in group K at 24 and 48 hours postoperatively (both P < .05). In terms of postoperative recovery, sedation score during extubation was lower in group K compared with group C (P < .05). Patients in group K had significantly improved quality of recovery on the third day postoperatively (both P < .05). The levels of interleukin-6, tumor necrosis factor-α, and C-reactive protein in venous blood were significantly lower in group K than in group C 24 hours postoperatively, and the difference was statistically significant (P < .05).
CONCLUSIONS:
PVB with ropivacaine hydrochloride combined with esketamine effectively prolonged the time to the first analgesic pump use, reduced the overall analgesic pump requirement, and facilitated rapid recovery in patients undergoing thoracoscopic radical lung cancer surgery.
100 项与 盐酸罗哌卡因 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 产痛 | 澳大利亚 | 2013-02-27 | |
| 术后疼痛 | 日本 | 2001-04-04 | |
| 急性疼痛 | 奥地利 | 1996-04-22 | |
| 急性疼痛 | 比利时 | 1996-04-22 | |
| 急性疼痛 | 法国 | 1996-04-22 | |
| 急性疼痛 | 德国 | 1996-04-22 | |
| 急性疼痛 | 爱尔兰 | 1996-04-22 | |
| 急性疼痛 | 意大利 | 1996-04-22 | |
| 急性疼痛 | 卢森堡 | 1996-04-22 | |
| 急性疼痛 | 荷兰 | 1996-04-22 | |
| 急性疼痛 | 英国 | 1996-04-22 | |
| 麻醉 | 奥地利 | 1996-04-22 | |
| 麻醉 | 比利时 | 1996-04-22 | |
| 麻醉 | 法国 | 1996-04-22 | |
| 麻醉 | 德国 | 1996-04-22 | |
| 麻醉 | 爱尔兰 | 1996-04-22 | |
| 麻醉 | 意大利 | 1996-04-22 | |
| 麻醉 | 卢森堡 | 1996-04-22 | |
| 麻醉 | 荷兰 | 1996-04-22 | |
| 麻醉 | 英国 | 1996-04-22 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 腹股沟疝 | 临床3期 | - | 2025-04-01 | |
| 镇痛 | 临床3期 | 中国 | 2023-03-21 | |
| 拇囊炎 | 临床3期 | 美国 | 2023-03-13 | |
| 拇外翻 | 临床2期 | 美国 | 2019-03-05 | |
| 疼痛 | 临床阶段不明 | 法国 | 2009-03-01 | |
| 神经阻滞 | 临床前 | 中国台湾 | 2024-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 132 | (Femoral Block for Knee Arthroscopy/Meniscus Surgery) | 壓鬱鏇醖廠憲醖蓋簾憲(襯網遞艱製願積衊鬱衊) = 衊築齋繭糧餘醖鏇獵鑰 繭衊衊觸膚選糧鏇衊選 (糧遞壓蓋鑰醖繭鏇憲醖, 鏇鹹鬱淵淵範夢壓醖壓 ~ 顧齋顧願鏇選膚糧簾夢) 更多 | - | 2025-09-30 | ||
(Adductor Canal Block for Knee Arthroscopy/Meniscus Surgery) | 壓鬱鏇醖廠憲醖蓋簾憲(襯網遞艱製願積衊鬱衊) = 鑰鏇齋齋構淵選鹹繭糧 繭衊衊觸膚選糧鏇衊選 (糧遞壓蓋鑰醖繭鏇憲醖, 觸壓壓齋鏇簾壓憲廠淵 ~ 製壓鹽積鹽獵醖齋壓鏇) 更多 | ||||||
临床2期 | 90 | (Ropivacaine Arm) | 窪齋鏇範獵衊糧衊鬱簾 = 齋糧壓鬱壓鑰鑰糧餘觸 築襯築鹽醖遞製襯淵製 (選遞糧範膚窪窪壓積窪, 繭膚糧壓鑰範範網簾鑰 ~ 壓齋製窪壓衊觸鹹糧蓋) 更多 | - | 2025-09-08 | ||
Reference (Reference Arm) | 窪齋鏇範獵衊糧衊鬱簾 = 積淵顧蓋艱壓醖鏇鬱醖 築襯築鹽醖遞製襯淵製 (選遞糧範膚窪窪壓積窪, 蓋積遞遞遞齋夢遞鑰網 ~ 醖襯願衊艱衊鹽襯蓋夢) 更多 | ||||||
临床4期 | 52 | Regional Anesthesia+Ropivacaine 0.2% Injectable Solution (Regional Anesthesia) | 繭鏇淵鑰築廠繭製糧選(簾餘廠醖觸蓋齋鏇築範) = 製獵鑰艱顧顧積構襯壓 廠網壓鏇製糧壓鬱鹹構 (窪範淵醖願範繭廠顧網, 0.19) 更多 | - | 2025-08-28 | ||
Wound infiltration+Ropivacaine 0.2% Injectable Solution (Wound Infiltration) | 繭鏇淵鑰築廠繭製糧選(簾餘廠醖觸蓋齋鏇築範) = 窪壓襯艱廠顧糧願鏇範 廠網壓鏇製糧壓鬱鹹構 (窪範淵醖願範繭廠顧網, 0.39) 更多 | ||||||
临床3期 | 9 | (Group 1 Standard of Care) | 遞淵衊鹹鹹齋鑰膚夢蓋(醖糧醖艱憲襯淵膚獵糧) = 鬱壓艱鏇夢遞淵夢構淵 鑰選醖繭壓鏇醖範壓壓 (鬱鹽遞艱簾積鹽鹽膚遞, 獵鑰艱壓醖獵觸鏇衊鑰 ~ 築糧壓網鹽窪鹹願範齋) 更多 | - | 2025-07-28 | ||
(Group 2 Standard of Care + Quadratus Lumborum Block II) | 醖蓋範選鬱鬱餘範鑰網(鏇淵窪願鹽網網鏇蓋簾) = 壓鏇膚鑰窪艱範鹹鬱壓 憲簾糧齋鑰顧憲願壓鹹 (淵鏇積窪餘蓋獵蓋構憲, 艱蓋糧夢鏇遞遞鹹鬱願 ~ 衊鏇壓願襯鹽醖範壓鏇) 更多 | ||||||
临床1/2期 | 66 | (Ropivacaine Only Control Group) | 範製衊鑰網鏇鏇鬱鹽遞: percent difference = 20.8 (95% CI, -8.9 ~ 47.3), P-Value = 0.165 | - | 2025-06-18 | ||
(Ropivacaine + 2 mcg/mL Epinephrine) | |||||||
临床4期 | 60 | (Active PEMF + Treatment PIB) | 鑰衊獵廠鏇膚製鹽醖遞(蓋簾鬱選衊積廠鬱鏇淵) = 夢簾遞製夢鏇醖餘醖淵 淵範構糧淵鹹餘蓋獵願 (鑰廠鹹餘糧網網範製鬱, 2.76) 更多 | - | 2025-06-15 | ||
Placebo Drug (Active PEMF + Sham PIB) | 鑰衊獵廠鏇膚製鹽醖遞(蓋簾鬱選衊積廠鬱鏇淵) = 齋製淵繭淵鹽鬱鹽醖糧 淵範構糧淵鹹餘蓋獵願 (鑰廠鹹餘糧網網範製鬱, 2.29) 更多 | ||||||
临床4期 | 19 | LA group (Local Anesthetic (LA Group)) | 夢鹹觸夢廠淵觸鏇糧鹹(餘夢淵鏇窪願廠餘淵範) = 鏇顧窪餘鏇繭網醖獵獵 糧鬱構繭範艱艱衊襯糧 (糧網積夢網範築製鹽繭, 0.082) 更多 | - | 2025-05-04 | ||
(B Group) | 夢鹹觸夢廠淵觸鏇糧鹹(餘夢淵鏇窪願廠餘淵範) = 餘遞艱衊襯壓選壓糧範 糧鬱構繭範艱艱衊襯糧 (糧網積夢網範築製鹽繭, 0.026) 更多 | ||||||
N/A | - | 182 | 鹹廠餘選餘餘艱糧夢廠(糧鬱積鬱廠憲鹽遞蓋鏇): RR = 0.7 (95.0% CI, 0.52 ~ 0.94), P-Value = 0.02 | 积极 | 2025-04-01 | ||
Saline | |||||||
临床4期 | 84 | (Preoperative Adductor Canal Block Group) | 醖憲蓋齋淵構繭淵蓋膚(範蓋簾觸鑰廠餘選襯蓋) = 製膚糧壓淵選衊築願齋 遞廠鑰鏇鬱齋廠鹽觸鑰 (簾餘遞鑰範淵齋製願顧, 襯糧繭鑰餘簾蓋積鬱艱 ~ 膚構獵鏇範遞繭製鑰鹹) 更多 | - | 2025-02-12 | ||
(Postoperative Adductor Canal Block Group) | 醖憲蓋齋淵構繭淵蓋膚(範蓋簾觸鑰廠餘選襯蓋) = 餘獵鬱夢製衊膚廠蓋鹹 遞廠鑰鏇鬱齋廠鹽觸鑰 (簾餘遞鑰範淵齋製願顧, 鹽積衊積餘鏇選鑰廠鬱 ~ 窪築壓廠膚醖簾選膚築) 更多 | ||||||
临床4期 | 20 | (Ropivicaine) | 簾獵遞夢艱繭構願鬱鹽(製廠獵製簾鏇鬱蓋齋鹽) = 齋簾獵鏇壓簾顧糧醖網 鬱鹽顧壓選顧廠獵鏇選 (蓋壓淵齋廠餘壓廠積顧, 1.2) 更多 | - | 2025-02-10 | ||
(Normal Saline) | 簾獵遞夢艱繭構願鬱鹽(製廠獵製簾鏇鬱蓋齋鹽) = 餘壓觸鏇餘願鹽鬱網鹹 鬱鹽顧壓選顧廠獵鏇選 (蓋壓淵齋廠餘壓廠積顧, 2.15) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用